135 related articles for article (PubMed ID: 2417985)
1. Evaluation of bleomycin, chlorozotocin, MGBG, and bruceantin in patients with advanced soft tissue sarcoma, bone sarcoma, or mesothelioma.
Amato DA; Borden EC; Shiraki M; Enterline HT; Rosenbaum C; Davis HL; Paul AR; Stevens CM; Lerner HJ
Invest New Drugs; 1985; 3(4):397-401. PubMed ID: 2417985
[TBL] [Abstract][Full Text] [Related]
2. Phase II evaluation of chlorozotocin in metastatic sarcomas.
Presant CA; Bartolucci AA
Med Pediatr Oncol; 1984; 12(1):25-7. PubMed ID: 6230516
[TBL] [Abstract][Full Text] [Related]
3. A Phase II study of Bruceantin (NSC-165, 563) in advanced malignant melanoma.
Arseneau JC; Wolter JM; Kuperminc M; Ruckdeschel JC
Invest New Drugs; 1983; 1(3):239-42. PubMed ID: 6678872
[TBL] [Abstract][Full Text] [Related]
4. Treatment of advanced soft tissue sarcoma with chlorozotocin: a phase II trial of the EORTC soft tissue and bone sarcoma group.
Mouridsen HT; Bramwell VH; Lacave J; Metz R; Vendrik C; Hild J; McCreanney J; Sylvester R
Cancer Treat Rep; 1981; 65(5-6):509-11. PubMed ID: 6453646
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of bruceantin in metastatic breast carcinoma.
Wiseman CL; Yap HY; Bedikian AY; Bodey GP; Blumenschein GR
Am J Clin Oncol; 1982 Aug; 5(4):389-91. PubMed ID: 7113961
[TBL] [Abstract][Full Text] [Related]
6. Chlorozotocin: phase II evaluation in patients with advanced sarcomas.
Sordillo PP; Magill GB; Gralla RJ
Cancer Treat Rep; 1981; 65(5-6):513-4. PubMed ID: 6453647
[No Abstract] [Full Text] [Related]
7. Phase I trial of bruceantin.
Garnick MB; Blum RH; Canellos GP; Mayer RJ; Parker L; Skarin AT; Li FP; Henderson IC; Frei E
Cancer Treat Rep; 1979; 63(11-12):1929-32. PubMed ID: 526926
[TBL] [Abstract][Full Text] [Related]
8. Phase I study on bruceantin administered on a weekly schedule.
Liesmann J; Belt RJ; Haas CD; Hoogstraten B
Cancer Treat Rep; 1981; 65(9-10):883-5. PubMed ID: 7273023
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of 6-diazo-5-oxo-L-norleucine versus aclacinomycin-A in advanced sarcomas and mesotheliomas.
Earhart RH; Amato DJ; Chang AY; Borden EC; Shiraki M; Dowd ME; Comis RL; Davis TE; Smith TJ
Invest New Drugs; 1990 Feb; 8(1):113-9. PubMed ID: 2188926
[TBL] [Abstract][Full Text] [Related]
10. ECOG phase II trials of MGBG, chlorozotocin, COM multidrug therapy in advanced measurable colorectal cancer.
Douglass HO; Lefkopoulou M; Davis HL; Taylor SG; Falkson G; Mittelman A; MacIntyre J; Engstrom PF
Am J Clin Oncol; 1988 Dec; 11(6):646-9. PubMed ID: 2973226
[TBL] [Abstract][Full Text] [Related]
11. Phase II evaluation of dibromodulcitol, ICRF-159, and maytansine for sarcomas.
Borden EC; Ash A; Enterline HT; Rosenbaum C; Laucius JF; Paul AR; Falkson G; Lerner H
Am J Clin Oncol; 1982 Aug; 5(4):417-20. PubMed ID: 6956236
[TBL] [Abstract][Full Text] [Related]
12. Initial clinical studies with bruceantin.
Bedikian AY; Valdivieso M; Bodey GP; Murphy WK; Freireich EJ
Cancer Treat Rep; 1979; 63(11-12):1843-7. PubMed ID: 526918
[TBL] [Abstract][Full Text] [Related]
13. Cis-dichlorodiammineplatinum(II) in advanced soft tissue and bony sarcomas: a Southwest Oncology Group Study.
Samson MK; Baker LH; Benjamin RS; Lane M; Plager C
Cancer Treat Rep; 1979; 63(11-12):2027-9. PubMed ID: 575067
[TBL] [Abstract][Full Text] [Related]
14. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
Antman K; Crowley J; Balcerzak SP; Rivkin SE; Weiss GR; Elias A; Natale RB; Cooper RM; Barlogie B; Trump DL
J Clin Oncol; 1993 Jul; 11(7):1276-85. PubMed ID: 8315425
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of methylglyoxal-bis-guanylhydrazone (methyl-GAG) in patients with soft-tissue sarcomas.
Sordillo PP; Magill GB; Welt S
Am J Clin Oncol; 1985 Aug; 8(4):316-8. PubMed ID: 3909804
[TBL] [Abstract][Full Text] [Related]
16. Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.
Grignani G; D'Ambrosio L; Pignochino Y; Palmerini E; Zucchetti M; Boccone P; Aliberti S; Stacchiotti S; Bertulli R; Piana R; Miano S; Tolomeo F; Chiabotto G; Sangiolo D; Pisacane A; Dei Tos AP; Novara L; Bartolini A; Marchesi E; D'Incalci M; Bardelli A; Picci P; Ferrari S; Aglietta M
Lancet Oncol; 2018 Oct; 19(10):1360-1371. PubMed ID: 30217671
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacology of bruceantin by radioimmunoassay.
Fong KL; Ho DH; Benjamin RS; Brown NS; Bedikian A; Yap BS; Wiseman CL; Kramer W; Bodey GP
Cancer Chemother Pharmacol; 1982; 9(3):169-72. PubMed ID: 7160053
[TBL] [Abstract][Full Text] [Related]
18. Phase II trials of maytansine, low-dose chlorozotocin, and high-dose chlorozotocin as single agents against advanced measurable adenocarcinoma of the pancreas. Gastrointestinal Tumor Study Group.
Cancer Treat Rep; 1985 Apr; 69(4):417-20. PubMed ID: 2859924
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of alpha-difluoromethylornithine and methyl-GAG.
Splinter TA; Romijn JC
Eur J Cancer Clin Oncol; 1986 Jan; 22(1):61-7. PubMed ID: 3082642
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of methylglyoxal-bis(guanylhydrazone) (MGBG) in patients with refractory multiple myeloma: an Eastern Cooperative Oncology Group (ECOG) study.
Winter JN; Ritch PS; Rosen ST; Oken MM; Wolter JM; Wiernik PH; O'Connell MJ
Cancer Invest; 1990; 8(2):143-6. PubMed ID: 2205334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
